Psychiatry Search
Psychiatry Psychiatry
bipolar%20disorder
BIPOLAR DISORDER
Bipolar I disorder is primarily defined by manic or mixed episodes that last for at least 7 days, or very severe manic symptoms needing immediate hospital care. The patient also has depressive episodes which may last for at least 2 weeks.
Bipolar II disorder is usually misdiagnosed. It is characterized by occurence of ≥1 major depressive episodes with at least 1 hypomanic episode.
Cyclothymic disorder or cyclothymia is a mild form of bipolar disorder. Patients have  episodes of hypomania alternating with mild depression that lasts for 2 years.
Rapid-cycling bipolar disorder patients have ≥4 episodes of major depression, mania, hypomania or mixed symptoms within a year.
Drug Information

Indication: Maintenance treatment of schizophrenia in adult patients.

Indication: Schizophrenia. Acute treatment of manic or mixed episodes associated w/ bipolar I disorder.

Indication: Patients w/ schizophrenia who are non-responsive to or intolerant of classic antipsychotics. Recurrent suicida...

Indication: Schizophrenia.

Indication: Acute & maintenance treatment of schizophrenia in adults.

Indication: Risperdal Schizophrenia including 1st episode psychoses, acute schizophrenic exacerbations, chronic schizophre...

Indication: Acute & maintenance treatment of schizoprenia. Acute manic episodes associated w/ bipolar I disorder.

Indication: Schizophrenia & acute manic episodes w/ bipolar I disorder.

Indication: Adjunctive or monotherapy in treatment of epilepsy for partial & generalized seizures, including tonic-clo...

Indication: Acute & maintenance treatment of schizophrenia. Alleviates secondary affective symptoms associated w/ schi...

1  /  4
1  /  4
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Psychiatry - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Beta-blockers may reduce mortality in patients with heart failure, renal dysfunction
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.
New from USPSTF: Breast cancer risk-reduction recommendations
Elvira Manzano, Yesterday

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.
UTI risk not raised with SGLT-2is in real-world study
Pearl Toh, 2 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
Lower HbA1c prolongs hypoglycaemia duration in type 2 diabetics
6 days ago
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.